Journal and News Scan

The debate continues over long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease. This study, based on the SWEDEHEART registry, analyzed 57,097 revascularized patients with NSTEMI and multivessel disease in Sweden from January 2005 to June 2022. The primary endpoint was all-cause mortality, encompassing both in-hospital and long-term mortality. 
 
Percutaneous coronary intervention was the primary therapy in 42,190 patients (73.9 percent), while 14,907 (26.1 percent) received CABG. During a median follow-up of 7.1 years, PCI was associated with higher risks of death (adjusted odds ratio [aOR] 1.67; 95 percent confidence interval [CI] 1.54-1.81) and MI (aOR 1.51; 95 percent CI 1.41-1.62), but there was no significant difference in stroke. Repeat revascularization was three times more likely to PCI (aOR 3.01; 95 percent CI 2.57-3.51), while heart failure risk was 15 percent higher (aOR 1.15; 95% CI 1.07-1.25). CABG provided longer survival within 15 years, especially in patients under 70 years of age, with left main disease or left ventricular dysfunction, though, this benefit diminished over shorter time horizons. 
 
The authors concluded that CABG is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy. 

This study analyzed mechanisms of repair failure after mitral valve repair using chordal replacement and annuloplasty for degenerative mitral regurgitation. Between 2003 and 2010, 344 patients underwent mitral valve repair at the German Heart Center Munich. After a mean follow-up of 9.7 years, 38 patients (11 percent) required reoperation, with causes of failure being disease progression (39.5 percent), technical failure (38.8 percent), and endocarditis (18.4 percent). Re-repair was performed in 28.9 percent of cases, often involving redo annuloplasty or chordal replacement. Mitral valve replacement was needed in 63.2 percent of cases, particularly in patients with mitral valve sclerosis. Redo mitral valve repair was more common for technical failure, while mitral valve replacement was more often needed for valve sclerosis.  

In this official statement, the European Society of Cardiology advocates for the evolution of the Medical Device Regulation (MDR) system to facilitate priority access for innovative devices addressing unmet needs and orphan cardiovascular medical devices in the European Union. It also calls for global regulatory harmonization to streamline cardiovascular medical device authorization across jurisdictions, enabling reprocessing of single-use devices, and encouraging early feasibility studies to assess initial safety and performance, thus accelerating device development and adoption. This report presents a proposal to improve medical device authorization worldwide while protecting patient safety. 

This study reported the initial experiences of 115 patients who underwent robot-assisted thoracic surgery using the da Vinci single-port robotic system. The procedures included thymectomy, mediastinal mass excision, anatomical pulmonary resection, esophagectomy, and esophageal tumor enucleation. No conversions to thoracotomy or sternotomy were required, and only one patient required conversion to video-assisted thoracic surgery, with minimal postoperative complications. The findings suggest that single-port robot-assisted thoracic surgery is feasible and safe, with the potential for expanded use as robotic technology continues to advance.